Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Sirolimus in Epidermolysis Bullosa Simplex
NCT02960997Phase 2Completed
- Sponsor
- Stanford University
- Start
- May 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sirolimus in epidermolysis bullosa simplex (EBS) (2 arms), sponsored by Stanford University. Primary endpoints: Foot Health Status Questionnaire, Foot Function Domain at Week 12, Foot Health Status Questionnaire, Physical Activity Domain at Week 12 and 1 more. Started May 2016; status: completed.
02
Drugs
sirolimus
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on NCT02960997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960997.